New hope for hard-to-treat lung cancer? early trial combines experimental drug, immunotherapy, and radiation.
NCT ID NCT07113691
First seen Nov 06, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This early-phase trial is testing a new drug called iadademstat, taken as a liquid by mouth, together with the immunotherapy atezolizumab and targeted radiation (SBRT) in people with extensive-stage small-cell lung cancer that has persisted, come back, or gotten worse after initial chemotherapy. The study will enroll about 15 adults and is primarily looking at safety—what side effects occur and at what doses. It is not yet designed to prove whether the combination works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iadademstat (oral drug) combined with atezolizumab (immunotherapy) and stereotactic body radiation therapy (SBRT)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced small-cell lung cancer that has not responded to initial therapy.
What could go wrong
This is a very early (Phase 1) and small (15 people) trial focused on safety, not yet on effectiveness. The combination may cause serious side effects or not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.